We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (SAFIR02_Breast)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02299999
Recruitment Status : Active, not recruiting
First Posted : November 24, 2014
Last Update Posted : March 9, 2022
Sponsor:
Collaborators:
Fondation ARC
AstraZeneca
Information provided by (Responsible Party):
UNICANCER

Tracking Information
First Submitted Date  ICMJE October 1, 2014
First Posted Date  ICMJE November 24, 2014
Last Update Posted Date March 9, 2022
Actual Study Start Date  ICMJE April 7, 2014
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 20, 2014)
Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm [ Time Frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 19, 2016)
  • progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm [ Time Frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
    To evaluate whether treatment with MEDI4736 improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer
  • overall survival in each substudy [ Time Frame: from randomization to death (any cause), up to 16 months ]
    To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) or MEDI4736 improves overall survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer
  • overall response rates and changes in tumor size in each substudy [ Time Frame: tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
    tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
  • evaluate safety, in each substudy [ Time Frame: toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart ]
    Toxicities are graded according to the CTCAE V4
  • efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1) [ Time Frame: tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
    tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
  • correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy [ Time Frame: from randomization or treatment initiation to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
    tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
Original Secondary Outcome Measures  ICMJE
 (submitted: November 20, 2014)
  • Overall survival in both arms [ Time Frame: from randomization to death (any cause), up to 16 months ]
  • Overall disease response rates and changes in tumor size in both arms [ Time Frame: tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
    tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
  • Disease response rate for each evaluated drug [ Time Frame: tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
    tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria
  • Number of patients presenting with acute or delayed toxicities to each drug [ Time Frame: toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart ]
    Toxicities are graded according to the CTCAE V4
  • Progression free and overall survival measured for each evaluated drug [ Time Frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Official Title  ICMJE PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Brief Summary Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with maintenance chemotherapy (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
Detailed Description

Screening phase:

New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic platforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing).

Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions have been met: stable or responding disease has been observed (investigator judgment) after 6 to 8 cycles of chemotherapy (or at least after 4 cycles of chemotherapy if stopped for toxicity) and targetable alteration has been identified by the Molecular Tumor Board (MTB).

If not eligible for the substudy 1 randomisation phase, patients can be considered as pre-eligible for the immune substudy 2 randomization phase when both following mandatory conditions are met: stable or responding disease (investigator judgment) is observed after 6 to 8 cycles of chemotherapy (or at least after 4 cycles if treatment was stopped due to toxicity) AND not eligible to randomization in the substudy 1 (because patient had no targetable alteration identified by the Molecular Tumor Board, or failed to have a genomic profile for the tumor [low tumor cells percentage, technical issue during genomic analysis, etc.], or a non inclusion criteria that precluded entry into the substudy 1)

Randomization phase:

The mandatory post-chemotherapy wash-out period, of 28 days for 21 or 28 day-cycle chemotherapies or of 15 days for weekly (except monoclonal antibodies) or daily chemotherapies,will provide time to achieve all the required tests and examinations.

The randomization program will allocate the following treatments with a 2:1 ratio in favor of Arm A of the considered substudy:

Substudy 1 : targeted therapies versus standard maintenance chemotherapy

  • Arm A1 / targeted arm: targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, or
  • Arm B1 / chemotherapy arm : maintenance chemotherapy (or no antineoplastic treatment in case of toxicity at the time of randomization)

Substudy 2 : immunotherapy versus standard maintenance chemotherapy

  • Arm A2 / immunotherapy maintenance arm: MEDI4736 or
  • Arm B2 / chemotherapy arm: chemotherapy continued as a maintenance chemotherapy (or no antineoplastic treatment in case of toxicity)
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Breast Cancer
Intervention  ICMJE
  • Drug: AZD2014
    Target: m-TOR
  • Drug: AZD4547
    Target: EGFR
  • Drug: AZD5363
    Target: AKT
  • Drug: AZD8931
    Target: HER2, EGFR
  • Drug: Selumetinib
    Target: MEK
    Other Name: ARRY-142866
  • Drug: Vandetanib
    Target: VEGF, EGFR
    Other Name: CAPRELSA
  • Drug: Bicalutamide
    target: Androgen receptor
    Other Name: Casodex
  • Drug: Olaparib
    Target: PARP
    Other Name: Lynparza
  • Drug: Anthracyclines
    DNA intercalation
    Other Name: Doxorubicin, Epirubicin, liposomal doxorubicin
  • Drug: Taxanes
    Target: mitotic tubulin and microtubules
    Other Names:
    • paclitaxel
    • docetaxel
  • Drug: cyclophosphamide
    Alkylating agents
    Other Names:
    • Novatrex
    • Imeth
  • Drug: DNA intercalators
    DNA intercalators
    Other Names:
    • capecitabine
    • 5-FU
    • gemcitabine
  • Drug: Methotrexate
    DNA intercalators
  • Drug: vinca alkaloids
    Target: mitotic tubulin and microtubules
    Other Names:
    • vinorelbine
    • vinblastine
    • vincristine
  • Drug: Platinum based chemotherapies
    Platinum based chemotherapies
    Other Names:
    • Platinum
    • carboplatin
    • cisplatin
  • Drug: Bevacizumab
    Target: VEGF
    Other Name: Avastin
  • Drug: Mitomycin C
    Alkylating agents
    Other Name: Ametycine
  • Drug: Eribulin
    Microtubule modulator
    Other Name: Halaven
  • Drug: MEDI4736
    Target: PD-L1
Study Arms  ICMJE
  • Experimental: Substudy 1: targeted agent
    Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
    Interventions:
    • Drug: AZD2014
    • Drug: AZD4547
    • Drug: AZD5363
    • Drug: AZD8931
    • Drug: Selumetinib
    • Drug: Vandetanib
    • Drug: Bicalutamide
    • Drug: Olaparib
  • Active Comparator: Substudy 1: standard maintenance therapy
    Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
    Interventions:
    • Drug: Anthracyclines
    • Drug: Taxanes
    • Drug: cyclophosphamide
    • Drug: DNA intercalators
    • Drug: Methotrexate
    • Drug: vinca alkaloids
    • Drug: Platinum based chemotherapies
    • Drug: Bevacizumab
    • Drug: Mitomycin C
    • Drug: Eribulin
  • Experimental: Substudy 2: Immunotherapy
    Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
    Intervention: Drug: MEDI4736
  • Active Comparator: Substudy 2: standard maintenance therapy
    Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
    Interventions:
    • Drug: Anthracyclines
    • Drug: Taxanes
    • Drug: cyclophosphamide
    • Drug: DNA intercalators
    • Drug: Methotrexate
    • Drug: vinca alkaloids
    • Drug: Platinum based chemotherapies
    • Drug: Bevacizumab
    • Drug: Mitomycin C
    • Drug: Eribulin
Publications * Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, Le Tourneau C, Sablin MP, Lacroix L, Enrico D, Miran I, Jovelet C, Bièche I, Soria JC, Bertucci F, Bonnefoi H, Campone M, Dalenc F, Bachelot T, Jacquet A, Jimenez M, André F. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020 Mar;31(3):377-386. doi: 10.1016/j.annonc.2019.11.006. Epub 2020 Jan 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 2, 2017)
1460
Original Estimated Enrollment  ICMJE
 (submitted: November 20, 2014)
460
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Screening phase:

Inclusion Criteria:

  • Women (or men) with histologically proven breast cancer
  • Metastatic relapse or progression or stage IV at diagnosis
  • No Her2 over-expression
  • Patients with metastases that can be biopsied, except bone metastases
  • Patients who are eligible for a first or a second line of chemotherapy in metastatic setting (left to the discretion of investigators), or who are currently treated with a first or second line of chemotherapy with a maximum of 2 cycles at the time of biopsy. Screening of patients currently treated with a second line chemotherapy should have a stable disease
  • For patients with ER+ disease, relapse or progression occurred during endocrine therapy, whatever the line, or less than 12 months after the end of endocrine therapy in adjuvant context
  • Age ≥18 years
  • WHO Performance Status 0/1
  • Presence of measurable target lesion according to RECIST criteria v1.1

Exclusion criteria:

  • Spinal cord compression and/or symptomatic or progressive brain metastases
  • Bone metastases when this is the only site of biopsiable disease
  • Patients with all target lesions in a previously irradiated region, except if clear progression has been observed prior to study in at least one of them
  • Patient who received more than 2 lines of chemotherapy at the time of the biopsy
  • Tumor progression observed with the current line of treatment when under 2nd line
  • Patients who already had a genomic profile (both CGH and NGS analysis) in which no SAFIR02 targetable alterations have been identified
  • Abnormal coagulation contraindicating biopsy
  • Inability to swallow
  • Major problem with intestinal absorption Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG Any factors increasing the risk of QTc prolongation or arrhythmic events Experience of any of the following in the preceding 12 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, past or current uncontrolled angina pectoris, congestive heart failure NYHA Grade ≥2, torsades de pointes, current uncontrolled hypertension, cardiomyopathy Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which requires steroid treatment or any evidence of clinically interstitial lung disease Previous or current malignancies of other histologies within the last 5 years, Evidence of severe or uncontrolled systemic disease (active bleeding diatheses, or active Hepatitis B, C and HIV)
  • diagnosis of acne rosacea, severe psoriasis and severe atopic eczema
  • Prior exposure to anthracyclines or mitoxantrone with cumulative exposure in excess of 360 mg/m² for doxorubicin, 720 mg/m² for epirubicin, or 72 mg/m² for mitoxantrone
  • Previous treatment with the same agent or in the same class as one of those used in the SAFIR02 trial (patients who received this previous targeted agent without the target prescreening are eligible but may not be eligible for randomisation in substudy 1 if the treatment allocated by the MTB is in the same class) History of retinal degenerative disease, eye injury or corneal surgery in the previous 3 months, past history of central serous retinopathy or retinal vein occlusion, intraocular pressure >21 mmHg, or uncontrolled glaucoma.
  • History of hemorrhagic or thrombotic stroke, TIA or other CNS bleeds
  • Renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome, renal tubular acidosis
  • Patients using drugs that are known potent inhibitors or potent inducers or substrates of cytochrome P450

Randomized phase:

Substudy 1:

Inclusion Criteria:

  • Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4 cycles of chemotherapy definitively stopped for toxicity reasons, and who are presenting a SD or PR at randomization
  • presenting at least one genomic alteration from the predefined list
  • Age ≥25 years for patients planned to receive AZD4547
  • 28-day wash-out period from chemo prior to randomization and grade ≤1 residual toxicities

Exclusion Criteria:

  • More than 2 previous lines of chemotherapy for metastatic disease before randomization
  • Life expectancy <3 months
  • Disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the last chemotherapy before 4 full cycles have been delivered
  • Less than 28 days from radiotherapy, less than 2 weeks from palliative radiation
  • Patients previously treated with a targeted agent in the same class as the agent to be given to the patient in substudy 1
  • Toxicities of grade ≥2 from any previous anti-cancer therapy
  • Altered haematopoietic or organ function
  • Mean resting corrected QT interval (QTc) >480 msec (or QTcF >450 msec) obtained from 3 consecutive ECGs
  • Left ventricular ejection fraction (LVEF) <55% (MUGA scan or Echocardiogram)
  • Altered ophthalmic conditions confirmed by an ophthalmology specialist for patients likely to be treated with AZD4547 orAZD8931 or Selumetinib
  • Patients using non-substitutable drugs, that are known to prolong QT interval or induce Torsades de Pointes, when they are supposed to be treated with vandetanib, AZD5363 or AZD8931

Substudy 2:

Inclusion Criteria:

  • Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4 cycles of chemotherapy definitively stopped for toxicity reasons, and who are presenting a SD or a RP at randomization
  • Patients not eligible to substudy 1
  • wash-out period of at least 15 days for weekly (except monoclonal antibodies) or daily chemotherapies or 28 days for other chemotherapies from last chemotherapy administration prior to randomization and grade ≤1 residual toxicities

Exclusion Criteria:

  • More than 2 previous lines of chemotherapy for metastatic disease before randomization
  • Life expectancy <3 months
  • Disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the last chemotherapy before 4 full cycles have been delivered
  • Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736
  • Toxicities of grade ≥2 from any previous anti-cancer therapy
  • Altered haematopoietic or organ function
  • Mean resting QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 consecutive ECGs using Bazett's Correction
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
  • Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
  • History of primary immunodeficiency
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02299999
Other Study ID Numbers  ICMJE UC-0105/1304
2013-001652-36 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party UNICANCER
Original Responsible Party Same as current
Current Study Sponsor  ICMJE UNICANCER
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Fondation ARC
  • AstraZeneca
Investigators  ICMJE
Principal Investigator: Fabrice ANDRE, Pr Gustave Roussy, Villejuif
PRS Account UNICANCER
Verification Date March 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP